Seres Therapeutics is laying off a quarter of its workforce as the microbiome biopharma conserves resources to take its bloodstream infection preventive treatment into phase 2. The Cambridge, ...
Seres Therapeutics has cut about 30% of its workforce and said goodbye to its chief scientific officer as it narrows its clinical efforts. It will instead focus on what it described as its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback